Febrile Neutropenia - Pipeline Insight, 2024

Febrile Neutropenia - Pipeline Insight, 2024

DelveInsight’s, Febrile Neutropenia - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Febrile Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Febrile Neutropenia Understanding

Febrile Neutropenia: Overview

Neutropenic fever is defined as a single oral temperature greater than or equal to 101 F, or a temperature greater than or equal to 100.4 F for at least an hour, with an absolute neutrophilic count (ANC) of less than 1500 cells/microliter. In severe neutropenia, the absolute neutrophil count (ANC) is less than 500 per microliter, or ANC is expected to decrease below 500 cells/microL in the next 2 hours. Febrile Neutropenia is the most common serious and common complication of cancer therapy. Neutropenic fever is the most common and serious complication associated with hematopoietic cancers or with patients receiving chemotherapeutic regimens for cancer. Neutropenic fever occurs when a neutropenic patient encounters an infectious pathogen. In this immunocompromised state, patients lose or have weakened immunity to fend off infections. The host barriers, such as the mucosal lining of the GI tract or sinuses, may be damaged, leading the host open to invasion from an infectious pathogen.

""Febrile Neutropenia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Febrile Neutropenia pipeline landscape is provided which includes the disease overview and Febrile Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Febrile Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Febrile Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Febrile Neutropenia. The therapies under development are focused on novel approaches to treat/improve Febrile Neutropenia.
• In May 2022, BeyondSpring presented new clinical data in the Chemotherapy-Induced Neutropenia.The DUBLIN-3 Phase 3 trial is a randomized, single blinded, active-controlled global trial that enrolled 559 patients with 2nd/3rd line NSCLC, EGFR wild type, with a measurable lung lesion. Patients were treated on a 21-day cycle with an infusion of docetaxel (75 mg/m2 on day 1) and plinabulin (30 mg/m2 on days 1 and 8) vs. docetaxel alone (75 mg/m2, day 1). The primary endpoint was overall survival. Secondary endpoints include ORR, PFS, grade 4 neutropenia, 2 year and 3 year OS rate and quality of life analysis. Plinabulin in combination with docetaxel (DP) showed statistically significant overall survival improvements compared to docetaxel alone (D) for the ITT population (DP: n=278; D: n=281).

This segment of the Febrile Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Febrile Neutropenia Emerging Drugs

• Plinabulin: BeyondSpring Pharmaceuticals

Plinabulin is an investigational small molecule that is in the new class of selective immunomodulating microtubule-binding agent with potential chemotherapy-induced neutropenia (CIN) prevention and anticancer benefits. It features a unique mechanism of action (MOA) compared to current standard-of-care chemotherapeutics and conventional microtubule-binding agents, which results in differentiated safety and efficacy profile.

Further product details are provided in the report……..

Febrile Neutropenia: Therapeutic Assessment

This segment of the report provides insights about the Febrile Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Febrile Neutropenia

There are approx. 10+ key companies which are developing the therapies Febrile Neutropenia. The companies which have their Febrile Neutropenia drug candidates in the most advanced stage, i.e Phase III include, Daewoong Pharmaceutical.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Febrile Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Recombinant proteins
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Febrile Neutropenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Febrile Neutropenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Febrile Neutropenia drugs.

Febrile Neutropenia Report Insights

• Febrile Neutropenia Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Febrile Neutropenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Febrile Neutropenia drugs?
• How many Febrile Neutropenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Febrile Neutropenia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Febrile Neutropenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Febrile Neutropenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daewoong Pharmaceutical
• RedHill Biopharma
• Allakos
• Hanmi Pharmaceutical
• Trio Medicines
• Bristol-Myers Squibb

Key Products

• Fexuprazan
• Ondansetron controlled-release
• Lirentelimab
• HIP 2101
• Netazepide
• Cendakimab